Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 266 | 44% |
| 2020 | 6 | 244 | 47% |
| 2021 | 8 | 253 | 51% |
| 2022 | 7 | 261 | 54% |
| 2023 | 9 | 311 | 57% |
| 2024 | 9 | 288 | 59% |
| 2025 from claims | – | 269 217–315 | 59% |
| 2026 forecast | – | 280 219–351 | 60% |
| 2027 forecast | – | 291 216–385 | 60% |
| 2028 forecast | – | 303 214–418 | 61% |
| 2029 forecast | – | 315 214–451 | 61% |
| 2030 forecast | – | 327 214–486 | 62% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Texas; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 87% hospital outpatient, 13% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 9 | 349+4.4%/yr | +4.4%/yr | 0.2 | 30% | 300 in 2030−2.5%/yr |
| Tennessee | 7 | 205+8.7%/yr | +8.7%/yr | 0.3 | 28% | 290 in 2030+6.2%/yr |
| North Carolina | 5 | 192+9.9%/yr | +9.9%/yr | 0.2 | 21% | 300 in 2030+7.5%/yr |
| South Carolina | 6 | 142+4.7%/yr | +4.7%/yr | 0.2 | 17% | 310 in 2030+14%/yr |
| Georgia | 4 | 121+12%/yr | +12%/yr | 0.1 | 0% | 230 in 2030+11%/yr |
| Maryland | 4 | 116+2.8%/yr | +2.8%/yr | 0.1 | 0% | 100 in 2030−2.1%/yr |
| Virginia | 3 | 115+6.7%/yr | +6.7%/yr | 0.1 | 0% | 150 in 2030+4.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 145 | 15,144−1.2%/yr | −1.2%/yr | 7.11.5× | 92% | 18,900 in 2030+3.8%/yr |
| Ear tubes & middle ear surgery | 2 | 785−4.7%/yr | −4.7%/yr | 0.41.1× | 37% | 690 in 2030−2.1%/yr |
| Sleep apnea & airway implants | 12 | 595+24%/yr | +24%/yr | 0.31.2× | 14% | 630 in 2030+0.9%/yr |
Cochlear implants in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Cochlear leads with 38% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 8 companies reported engagement with Texas’s surgeons worth $43K in consulting, speaking, meals and travel tied to these products, about $4,817 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.